Data as of Mar 10
| -0.28 / -1.83%|
The 8 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 23.00, with a high estimate of 30.00 and a low estimate of 20.00. The median estimate represents a +53.44% increase from the last price of 14.99.
The current consensus among 8 polled investment analysts is to Buy stock in Keryx Biopharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.